Lazar Safaniev

Mr. Lazar Safaniev


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IKIgor Kvetnoy
Igor Kvetnoy
OKOleg Kheyfets
Oleg Kheyfets
LSLazar Safaniev
Lazar Safaniev
VKVladimir Kheifets
Vladimir Kheifets
Ekaterina S. MironovaEkaterina S. Mironova
Ekaterina S. Mironova
AGAnna Gavrilova
Anna Gavrilova
Cognitive disorders present significant medical and social challenges nowadays, due to their high prevalence, progressive course and a lack of effective methods for treatment of neurodegenerative diseases and comorbid pathologies. An important area of research is the identification of molecular biomarkers that reflect early pathophysiological changes and facilitate a more accurate biological characterization of cognitive impairment. This study provides an overview of the most relevant signaling molecules for diagnosing cognitive disorders. It presents data on the effectiveness of using comprehensive panels of molecular biomarkers in clinical practice, including β-amyloid, CD34, claudin, DRP1, endothelin-1, NF-kB, PINK1, RAGE, S100, α-synuclein, and tau protein, in patients with Alzheimer’s disease (AD) and vascular dementia (VD). The study results demonstrate that cumulative changes in the expression of signaling molecules reflect various neurodegenerative and vascular-associated biological processes. The data obtained are comparative in nature and require further validation before potential clinical application.

13 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
IKIgor Kvetnoy
Igor Kvetnoy
OKOleg Kheyfets
Oleg Kheyfets
LSLazar Safaniev
Lazar Safaniev
VKVladimir Kheifets
Vladimir Kheifets
Ekaterina S. MironovaEkaterina S. Mironova
Ekaterina S. Mironova
AGAnna Gavrilova
Anna Gavrilova
Cognitive disorders present significant medical and social challenges nowadays, due to their high prevalence, progressive course and a lack of effective methods for treatment of neurodegenerative diseases and comorbid pathologies. An important path for solving this problem is the search for reliable biomarkers that allow for early and differential diagnosis, especially in view of the similarity between clinical manifestations of different forms of dementia. This study provides an overview of the most relevant signaling molecules for diagnosing cognitive disorders. It presents data on the effectiveness of using comprehensive panels of molecular biomarkers in clinical practice, including β-amyloid, CD34, claudin, DRP1, endothelin-1, NF-kB, PINK1, RAGE, S100, α-synuclein, and tau protein, in patients with Alzheimer's disease (AD) and vascular dementia (VD). The study results demonstrate a high diagnostic relevance of the combined use of signaling molecules as a biomarker panel for screening and differentiating neurodegenerative diseases.

21 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
IKIgor Kvetnoy
Igor Kvetnoy
OKOleg Kheifets
Oleg Kheifets
LSLazar Safaniev
Lazar Safaniev
VKVladimir Kheifets
Vladimir Kheifets
Ekaterina S. MironovaEkaterina S. Mironova
Ekaterina S. Mironova
KPKyril Prashchayeu
Kyril Prashchayeu
Alzheimer's disease (AD) remains one of the most significant medical and social problems nowadays, which is due to its high prevalence, progressive course and a lack of effective treatment methods. The most important path for solving this issue is the search for reliable biomarkers which allow for the early and differential diagnosis of AD, especially in the context of similarity of its clinical manifestations to other forms of dementia, such as vascular dementia, for example. This study provides a comparative analysis of the expression of certain biomarkers involved in the neurodegeneration such as β-amyloid, CD34, claudin, DRP1, endothelin-1, NF-kB, PINK1, RAGE, S100, α-synuclein, and tau protein in buccal epithelium samples from patients with AD, vascular dementia, and from healthy persons. The obtained results made it possible to form a panel of molecular markers, including α-synuclein, RAGE, PINK1, and phosphorylated tau protein for the differential diagnosis of AD.

28 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
IKIgor Kvetnoy
Igor Kvetnoy
OKOleg Kheifets
Oleg Kheifets
LSLazar Safaniev
Lazar Safaniev
VKVladimir Kheifets
Vladimir Kheifets
Ekaterina S. MironovaEkaterina S. Mironova
Ekaterina S. Mironova
AIAndrei Ilnitski
Andrei Ilnitski
Cognitive impairment screening is an important issue in modern biomedicine. Neuropsychological tests have their limitations and, in some cases, fail to ensure an objective assessment of the dementia presence in individuals, especially in early stages of the disease development. In this study, we have investigated the expression of signaling molecules in the buccal epithelium, which are involved in the biochemical mechanisms of cognitive impairment caused by neurovascular pathology, in order to develop a diagnostic panel of molecular markers for dementia. Buccal epithelial samples from 146 participants, including 100 patients with vascular dementia (VD) and 46 healthy volunteers, were analyzed using immunocytochemistry. Based on the obtained results, a diagnostic panel for vascular dementia screening was developed, including such markers as β-amyloid, NF-κB, tau protein, claudin, and S100 protein. The buccal epithelium has been found to provide a convenient source of biomaterial for non-invasive diagnosis of cognitive disorders caused by neurovascular pathologies.